|
Biolinerx Ltd. (BLRX) DCF Valoración
IL | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BioLineRx Ltd. (BLRX) Bundle
¡Aumente la eficiencia y mejore la precisión con nuestra calculadora DCF (BLRX)! Equipado con datos reales de Biolinex Ltd. y supuestos personalizables, esta herramienta le permite pronosticar, analizar y valorar Biolinex Ltd. como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -27.2 | -22.0 | -25.3 | -28.5 | -57.1 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 |
EBITDA, % | 100 | 100 | 100 | 100 | -1188.77 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .9 | .9 | .7 | .7 | 1.4 | 4.1 | 4.1 | 4.1 | 4.1 | 4.1 |
Depreciation, % | 100 | 100 | 100 | 100 | 28.83 | 85.77 | 85.77 | 85.77 | 85.77 | 85.77 |
EBIT | -28.1 | -22.9 | -26.0 | -29.2 | -58.4 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 |
EBIT, % | 100 | 100 | 100 | 100 | -1217.6 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 27.5 | 22.6 | 57.1 | 51.1 | 43.0 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .6 | .1 | .1 | .7 | .7 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 14.75 | 82.95 | 82.95 | 82.95 | 82.95 | 82.95 |
Inventories | .0 | .0 | .0 | -41.2 | 2.0 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 |
Inventories, % | 100 | 100 | 100 | 100 | 40.69 | 88.14 | 88.14 | 88.14 | 88.14 | 88.14 |
Accounts Payable | 7.8 | 5.9 | 5.6 | 7.0 | 10.9 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 226.44 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.1 | .0 | -.1 | -.3 | -.3 | -.1 | -.1 | -.1 | -.1 | -.1 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | -6.19 | -1.24 | -1.24 | -1.24 | -1.24 | -1.24 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -29.6 | -23.6 | -27.1 | -22.1 | -58.4 | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -21.6 | -24.1 | -26.8 | 20.3 | -96.6 | -4.8 | 6.8 | 6.8 | 6.8 | 6.8 |
WACC, % | 13.12 | 13.12 | 13.12 | 11.08 | 13.12 | 12.71 | 12.71 | 12.71 | 12.71 | 12.71 |
PV UFCF | ||||||||||
SUM PV UFCF | 13.8 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 7 | |||||||||
Terminal Value | 65 | |||||||||
Present Terminal Value | 36 | |||||||||
Enterprise Value | 49 | |||||||||
Net Debt | 7 | |||||||||
Equity Value | 42 | |||||||||
Diluted Shares Outstanding, MM | 64 | |||||||||
Equity Value Per Share | 0.65 |
What You Will Receive
- Comprehensive Financial Model: BioLineRx Ltd.’s actual data facilitates accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automated updates allow you to view results immediately as you adjust parameters.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive Data: BioLineRx Ltd.'s historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Monitor BioLineRx Ltd.'s intrinsic value recalculating instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing BioLineRx Ltd.'s preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results in Real-Time: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
- 5. Utilize with Assurance: Present expert valuation insights to back your strategic decisions.
Why Choose This Calculator for BioLineRx Ltd. (BLRX)?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to BioLineRx’s valuation as you modify inputs.
- Pre-Loaded Data: Comes with BioLineRx’s actual financial information for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling BioLineRx Ltd. (BLRX) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to BioLineRx Ltd. (BLRX).
- Consultants: Deliver professional valuation insights regarding BioLineRx Ltd. (BLRX) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like BioLineRx Ltd. (BLRX) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to BioLineRx Ltd. (BLRX).
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: BioLineRx Ltd.'s (BLRX) historical and projected financials preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results.